AlphaMol

AlphaMol, established in 2020, is a biopharmaceutical company focused on AI-assisted new drug discovery. It primarily utilizes biocomputing, artificial intelligence, and innovative biotechnology for novel drug development. With the goal of addressing the weak technical capabilities in China's new drug research and development, AlphaMol’s product development strategy targets major human diseases, particularly those related to GPCR signaling pathways.